CFLAR and renal cell carcinoma: Anisomycin in renal cell carcinoma cells can mediate Bcl-2/c-FLIP(L)/Mcl-1/death receptor 4 (DR4) to promote cell apoptosis and exert anti-tumor effects (54, 55).